PreludeDx Receives FDA Breakthrough Device Designation for DCISionRT® Test for DCIS Breast Cancer Patients PreludeDx (PRNewsfoto/PreludeDx)
January 17, 2025
Prelude Corporation, a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation for its DCISionRT® test.
Thea Tlsty is the lead UCSF inventor.